- Home
- CVSA vs CRNX Comparison
CVSA vs CRNX Comparison
Compare CVSA & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVSA | CRNX |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.9B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CVSA | CRNX |
|---|---|---|
| Price | $116.20 | $36.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $150.00 | $74.78 |
| AVG Volume (30 Days) | 289.4K | ★ 1.0M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,039,000.00 |
| Revenue This Year | $9.83 | $722.66 |
| Revenue Next Year | $6.62 | $183.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $96.08 | $24.10 |
| 52 Week High | $116.03 | $57.99 |
Technical Indicators
Market Signals| Indicator | CVSA | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 80.91 | 37.03 |
| Support Level | $103.59 | $33.23 |
| Resistance Level | N/A | $37.23 |
| Average True Range (ATR) | 3.60 | 1.49 |
| MACD | 1.29 | 0.22 |
| Stochastic Oscillator | 93.18 | 53.29 |
Price Performance
Historical ComparisonAbout CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.